NCT02598310View on ClinicalTrials.gov

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Breast CancerEstrogen Receptor Negative NeoplasmHER-2 Positive Breast Cancer
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel 260mg/m2 q3w

DRUG

Trastuzumab

trastuzumab 6 mg/kg (8 mg/kg as the loading dose)

Trial Locations (1)

5698686

Osaka Medical College, Takatsuki

Sponsors
All Listed Sponsors
lead

Osaka Medical College

OTHER

NCT02598310 - Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter